HIV

New York Attorney General Letitia James announced a lawsuit filed against 2 former chief executive officers of Turing Pharmaceuticals, now known as Vyera Pharmaceuticals: “Pharma Bro” Martin Shkreli, currently serving a 7-year sentence in federal prison for securities fraud, a crime that took place before the launch of Vyera, and his business partner Kevin Mulleady.

Chinese health authorities are testing an HIV drug, lopinavir and ritonavir, as a potential treatment for the new coronavirus; a debate is growing over the efficacy of the sole drug approved to prevent preterm birth; the Trump administration threatens to withhold Califonia’s federal funding due to its abortion coverage requirements.

Mucosa-associated invariant T cells (MAIT cells) are a subset of the T-cell population. Their function and activity during the acute stage of HIV infection adds to the knowledge of immune system activation at this stage and could lead to possible new treatment interventions.

Truvada and Descovy are both manufactured by Gilead Sciences and used to treat HIV-1 infection and as pre-exposure prophylaxis (PrEP) in adult and pediatric patients.

Although the researchers state that more studies are needed to validate their findings, they found that patients who also had HIV, HBV, or HCV who were being treated with ICI therapy had similar rates of efficacy and toxicity to patients without chronic viral infections.

Nigeria has a population of almost 204 million. Of those, 3.1% of adults, or 3.5 million, are living with HIV. The accompanying death anxiety of people living with HIV and AIDS has not been studied in depth.

There are 12 clinical trials underway investigating various combination treatments for HIV and AIDS, but a cure remains elusive. Few studies have attempted to qualify and quantify the risk HIV-positive individuals claim they would take if it meant a cure could result.

The report suggests that removing barriers to coverage, as well as reducing medication costs for people with private insurance, would help decrease cost-related nonadherence to HIV therapies.

The use of antiretroviral therapy has allowed patients with HIV to have a life expectancy that approaches the lifespan of those without HIV. Despite this progress, however, HIV-associated neurocognitive disorders remain prevalent, and range from mild problems with memory, language, and reasoning to more severe HIV-associated dementia.

HIV-positive individuals face greater risks of kidney and liver diseases, cardiovascular events, osteoporosis, hepatitis C, and cancer. Clinical trials and research advances into the cause and development of the comorbid conditions are needed.

People living with HIV/AIDS (PLWHA) may be at a greater risk for a variety of chronic illnesses and may require additional care as the older PLWHA population increases, a recent study suggested.

A second study, slated for next year, will continue these infants on antiretroviral treatment with 2 experimental monoclonal antibodies, hoping the medications produce viral suppression—and testing the effects of temporarily stopping them—so that they don’t have to eventually initiate the standard triplet therapy that most older patients typically take. For adults, most treatments for HIV come from the cancer field, and are inflammatory, and are not safe enough to apply in children. An ongoing debate is when is it appropriate to begin these therapies in children.

It is important to take into account individual complexities such as comorbidities and pill burden when selecting antiretroviral therapy regimens for individuals living with HIV.

A recent commentary discusses the need to uncover diagnostic and prognostic biomarkers for HIV-associated neurocognitive disorder (HAND).

Activists seek to block Gilead’s patent extension for HIV drug tenofovir alafenamide; 2.1 million teens are using 1 or more tobacco products; African American and low-income mothers are less likely to seek treatment for postpartum depression.

The cost of the expensive treatment varies, based on insurance coverage or lack thereof, and is often out of financial reach of the uninsured.

The Medical Monitoring Project (MMP)—a national population-based behavioral and clinical surveillance system of adults diagnosed with HIV in the United States—provides information for monitoring progress of national treatment and prevention goals and is the only source of annual population-based data of those with HIV, according to a recent report.

Predisposing risk factors include less than a high school education and hepatitis C coinfection.

Under the ACA, patients with HIV in Medicaid expansion states have greater access to care.

A House committee approves a bill to ban all flavored tobacco products; anal cancer rates are on the rise; the debate continues over competing healthcare measures.

A recent study, published by JMIR Research Protocols, demonstrated the effectiveness of implementing a digital HIV care navigation intervention for young racial and ethnic minority men and transwomen.

Greater rates of adherence and persistence seen among patients on a single-tablet regimen.

The report emphasizes the need for maximizing the implementation and improving treatment and prevention tools to fight HIV because adherence challenges remain.

HHS takes action against Gilead; a report on fears of seasonal workers in Montana; the latest CDC data on preventable deaths show differences between urban and rural areas.

CDC recommends that young men who have sex with men have an HIV test every 6 months.